Spesolimab (Spevigo)
What is spesolimab?
Spesolimab (Spevigo) is a targeted biologic medication used for generalized pustular psoriasis, also called GPP. GPP is a rare but serious inflammatory form of psoriasis that can cause widespread painful redness and pustules and may require urgent specialty care.
Because GPP behaves very differently from ordinary plaque psoriasis, this medication is generally discussed in a more specialized setting than routine psoriasis treatments.
How does spesolimab work?
Spesolimab works by blocking the interleukin-36 receptor pathway, which is an important inflammatory pathway in generalized pustular psoriasis. This makes it a very targeted treatment for a disease that behaves differently from typical plaque psoriasis.
Its role is tied to the biology of GPP specifically, rather than to the broader biologic pathways more commonly discussed for plaque psoriasis.
What are possible side effects of spesolimab?
Possible side effects can include:
Fatigue
Nausea
Headache
Infusion-related reactions or injection-related reactions depending on the treatment setting
Infections in some patients
Because GPP can be a severe condition, treatment decisions are generally made in close coordination with specialists.
How is spesolimab used?
Spesolimab is used under specialist supervision. The exact treatment approach depends on whether the goal is treatment of an active flare or ongoing disease control when a patient is not currently flaring.
The intravenous formulation is used for treatment of a GPP flare. The subcutaneous formulation is used for treatment when not experiencing a flare, and current labeling extends that use to adults and selected patients 12 years of age and older who meet weight criteria. Because GPP can be serious, treatment planning may involve urgent evaluation, close follow-up, and coordination with hospital-level care in severe cases.